MCID: CNT046
MIFTS: 49

Central Nervous System Vasculitis

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Central Nervous System Vasculitis

MalaCards integrated aliases for Central Nervous System Vasculitis:

Name: Central Nervous System Vasculitis 12 15
Vasculitis, Central Nervous System 74

Classifications:



External Ids:

Disease Ontology 12 DOID:525
MeSH 45 D020293
NCIt 51 C84622
UMLS 74 C0751878

Summaries for Central Nervous System Vasculitis

Disease Ontology : 12 A vasculitis that is characterized by inflammation of blood vessel walls in the brain or spine.

MalaCards based summary : Central Nervous System Vasculitis, also known as vasculitis, central nervous system, is related to vasculitis and purpura. An important gene associated with Central Nervous System Vasculitis is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Prednisone and Hormones have been mentioned in the context of this disorder. Affiliated tissues include brain, lung and bone, and related phenotypes are hematopoietic system and immune system

Related Diseases for Central Nervous System Vasculitis

Diseases related to Central Nervous System Vasculitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 331)
# Related Disease Score Top Affiliating Genes
1 vasculitis 31.4 CRP MPO TNF
2 purpura 30.4 CRP IL6 TNF
3 human immunodeficiency virus infectious disease 30.1 IFNG IL6 TNF
4 familial mediterranean fever 29.9 CRP IL1B TNF
5 relapsing polychondritis 29.9 CRP IFNG IL6
6 cytomegalovirus infection 29.8 IL1B IL6 TNF
7 uveitis 29.8 IFNG IL17A TNF
8 human immunodeficiency virus type 1 29.7 CDK9 IFNG IL6 TNF
9 microscopic polyangiitis 29.6 HLA-DRB1 MPO TNF
10 meningitis 29.6 CRP IFNG IL1B IL6 TNF
11 toxoplasmosis 29.3 IFNG IL1B IL6 TNF
12 leptospirosis 29.1 CRP IFNG IL1B IL6 TNF
13 nervous system disease 29.1 CRP IFNG IL1B IL6 TNF
14 central nervous system disease 28.9 IFNG IL17A IL1B IL6 TNF
15 behcet syndrome 28.7 CRP IFNG IL17A IL1B IL6 TNF
16 arthritis 28.6 HLA-DRB1 IFNG IL17A IL1B IL6 TNF
17 multiple sclerosis 28.6 HLA-DRB1 IFNG IL17A IL1B IL6 TNF
18 rheumatoid arthritis 28.4 CRP HLA-DRB1 IFNG IL17A IL1B IL6
19 systemic lupus erythematosus 28.0 CRP HLA-DRB1 IFNG IL17A IL1B IL6
20 primary angiitis of the central nervous system 12.0
21 cartilage disease 10.5 CRP TNFRSF10A
22 neutrophilia, hereditary 10.4 CRP IL6
23 spinal disease 10.4 CRP IL6
24 acute cholangitis 10.4 CRP IL6
25 hirata disease 10.4 HLA-DRB1 TNFRSF10A
26 cold agglutinin disease 10.4 CRP IL6
27 cryopyrin-associated periodic syndrome 10.4 CRP IL6
28 salpingitis 10.4 CRP TNF
29 drug reaction with eosinophilia and systemic symptoms 10.4 CRP TNF
30 posterior scleritis 10.4 TNF TNFRSF10A
31 retinitis pigmentosa 55 10.3 IL6 TNF
32 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 IL6 TNF
33 critical limb ischemia 10.3 IL6 TNF
34 juvenile ankylosing spondylitis 10.3 IL6 TNF
35 null-cell leukemia 10.3 IL6 TNF
36 leukomalacia 10.3 IL6 TNF
37 posterior urethral valves 10.3 IL6 TNF
38 scorpion envenomation 10.3 IL6 TNF
39 cardiogenic shock 10.3 IL6 TNF
40 streptococcal toxic-shock syndrome 10.3 IL6 TNF
41 relapsing fever 10.3 CRP TNF
42 beryllium disease 10.3 HLA-DRB1 TNF
43 berylliosis 10.3 HLA-DRB1 IFNG
44 eosinophilia-myalgia syndrome 10.3 HLA-DRB1 IFNG
45 b-cell growth factor 10.3 IFNG IL6
46 suppurative otitis media 10.3 CRP IL1B
47 pericoronitis 10.3 CRP IL1B
48 schnitzler syndrome 10.3 CRP IL1B
49 clostridium difficile colitis 10.3 CCR6 IL1B
50 chickenpox 10.3

Graphical network of the top 20 diseases related to Central Nervous System Vasculitis:



Diseases related to Central Nervous System Vasculitis

Symptoms & Phenotypes for Central Nervous System Vasculitis

MGI Mouse Phenotypes related to Central Nervous System Vasculitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.56 CCR6 IFNG IL17A IL1B IL6 MPO
2 immune system MP:0005387 9.28 CCR6 CRP IFNG IL17A IL1B IL6

Drugs & Therapeutics for Central Nervous System Vasculitis

Drugs for Central Nervous System Vasculitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 99)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
2 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8
Infliximab Approved Phase 3,Phase 2 170277-31-3
9
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 2921-57-5
10
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 50-24-8 5755
12
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 302-25-0
13
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
14
leucovorin Approved Phase 3,Phase 2 58-05-9 143 6006
15
Hydroxychloroquine Approved Phase 3 118-42-3 3652
16
Adalimumab Approved Phase 3 331731-18-1 16219006
17
Etanercept Approved, Investigational Phase 3 185243-69-0
18
Alendronate Approved Phase 3 66376-36-1, 121268-17-5 2088
19
Abatacept Approved Phase 3,Phase 2 332348-12-6 10237
20
Bosentan Approved, Investigational Phase 3 147536-97-8 104865
21
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
23
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
24
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
25
Prednisolone hemisuccinate Experimental Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 2920-86-7
26 Upadacitinib Investigational Phase 3 1310726-60-3
27 Gastrointestinal Agents Phase 3,Phase 2,Not Applicable
28 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
29 Antirheumatic Agents Phase 3,Phase 2,Not Applicable
30 Immunologic Factors Phase 3,Phase 2,Not Applicable
31 Immunosuppressive Agents Phase 3,Phase 2,Not Applicable
32 Anti-Infective Agents Phase 3,Not Applicable
33 Methylprednisolone Acetate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
34 Antiemetics Phase 2, Phase 3,Phase 3,Not Applicable
35 Protective Agents Phase 2, Phase 3,Phase 3,Not Applicable
36 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 3,Not Applicable
37 Neuroprotective Agents Phase 2, Phase 3,Phase 3,Not Applicable
38 Autonomic Agents Phase 2, Phase 3,Phase 3,Not Applicable
39 Prednisolone acetate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
40 Pharmaceutical Solutions Phase 3,Not Applicable
41 Folate Phase 3,Phase 2
42 Antimetabolites, Antineoplastic Phase 3,Phase 2
43 Vitamin B9 Phase 3,Phase 2
44 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
45 Antimetabolites Phase 3,Phase 2
46 Vitamin B Complex Phase 3,Phase 2
47 Folic Acid Antagonists Phase 3,Phase 2
48 Antiparasitic Agents Phase 3
49 Antimalarials Phase 3
50 Antiprotozoal Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 96)
# Name Status NCT ID Phase Drugs
1 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
2 Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients Completed NCT01169597 Phase 4 prednisone
3 Tocilizumab Plus a Short Prednisone Taper for GCA Recruiting NCT03726749 Phase 4 Tocilizumab;Prednisone
4 Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission. Recruiting NCT03244709 Phase 4 Tocilizumab
5 Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica Unknown status NCT01423591 Phase 3 infliximab;inactive powder
6 An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) Completed NCT01791153 Phase 3 Tocilizumab;Prednisone;Tocilizumab Placebo;Prednisone Placebo;Corticosteroids;Methotrexate
7 Hydroxychloroquine in Giant Cell Arteritis Completed NCT00430807 Phase 3 hydroxychloroquine/placebo
8 Timed Release Tablet Prednisone in Polymyalgia Rheumatica Completed NCT00836810 Phase 2, Phase 3 Timed Release Tablet Prednisone;Prednisolone
9 HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis Completed NCT00305539 Phase 3 adalimumab;placebo
10 Etanercept Treatment in the Early Course of Polymyalgia Rheumatica Completed NCT00524381 Phase 3 Etanercept (Enbrel);Sodium chloride (placebo)
11 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
12 A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis Recruiting NCT03725202 Phase 3 Upadacitinib;Corticosteroid (CS)
13 Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA Recruiting NCT03600805 Phase 3 Sarilumab SAR153191;Sarilumab matching placebo;Prednisone;Prednisone matching placebo
14 Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS Recruiting NCT03632187 Phase 3 Abatacept;Placebos
15 Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica Recruiting NCT03600818 Phase 3 Sarilumab SAR153191 (REGN88);Sarilumab-matching placebo;Prednisone;Prednisone-matching placebo;Prednisone
16 A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE) Recruiting NCT03263715 Phase 3 Tocilizumab Prefilled Syringe [Actemra];Placebos;Glucocorticoids
17 Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE Recruiting NCT02908217 Phase 3 Tocilizumab;Placebo
18 An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) Active, not recruiting NCT03202368 Phase 3 Tocilizumab
19 MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial Not yet recruiting NCT03892785 Phase 3 Prednisone treatment;Tocilizumab treatment;Methotrexate treatment
20 Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO Not yet recruiting NCT03841734 Phase 3 treatment
21 Giant Cell Arteritis and Anakinra Trial Not yet recruiting NCT02902731 Phase 3 PLACEBO;ANAKINRA
22 Treatment With Leflunomide in Patients With Polymyalgia Rheumatica Not yet recruiting NCT03576794 Phase 3 Leflunomide 20 mg;Prednisolone
23 Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis Terminated NCT02531633 Phase 2, Phase 3 Sirukumab;Placebo to match sirukumab;Prednisone;Placebo to match prednisone
24 A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR Terminated NCT01821040 Phase 3 Lodotra®;Prednisone IR (immediate release)
25 A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA) Withdrawn NCT03192969 Phase 3 Abatacept;Glucocorticoid Treatment
26 Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica Withdrawn NCT02899026 Phase 3 Sirukumab;Placebo to match sirukumab;Prednisone /Prednisone placebo
27 Phase Ib Study of SC Milatuzumab in SLE Unknown status NCT01845740 Phase 1, Phase 2 milatuzumab;Placebo
28 Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. Completed NCT01910038 Phase 2 corticoids+ tocilizumab 8mg/Kg/4 weeks
29 Tocilizumab for Patients With Giant Cell Arteritis Completed NCT01450137 Phase 2 Tocilizumab + Glucocorticoids (GCs);Placebo + Glucocorticoids (GCs)
30 Tocilizumab Effect iN pOlymyalgia Rheumatica Completed NCT01713842 Phase 2 TCZ
31 Study of Tocilizumab to Treat Polymyalgia Rheumatica Completed NCT01396317 Phase 2 Tocilizumab
32 Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis Completed NCT00556439 Phase 2 Abatacept;Placebo
33 Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis Completed NCT00004686 Phase 2 methotrexate;prednisone
34 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
35 KPL-301 for Subjects With Giant Cell Arteritis Recruiting NCT03827018 Phase 2
36 A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis Recruiting NCT03765788 Phase 2 Prednisolone;Placebo to match Secukinumab, s.c.
37 Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab Recruiting NCT03745586 Phase 1, Phase 2 Tocilizumab;Glucocorticoids
38 Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis Recruiting NCT03711448 Phase 2 prednisone treatment;prednisone and ustekinumab treatment
39 Baricitinib in Relapsing Giant Cell Arteritis Recruiting NCT03026504 Phase 2 Baricitinib
40 Ustekinumab for the Treatment of Giant Cell Arteritis Recruiting NCT02955147 Phase 1, Phase 2 Ustekinumab;Prednisone
41 Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA) Not yet recruiting NCT03812302 Phase 2
42 Delayed Release Prednisone in PMR Terminated NCT02702778 Phase 2 Delayed-Release (DR) Prednisone;Immediate Release (IR) Prednisone
43 A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica Terminated NCT01364389 Phase 2 AIN457;ACZ885;Prednisone;Placebo
44 A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis Terminated NCT00076726 Phase 2 Infliximab
45 MRI Superficial Temporal Artery Completed NCT00188448 Phase 1
46 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA). Not yet recruiting NCT03923738 Phase 1 Tocilizumab
47 Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Not yet recruiting NCT03656627 Phase 1 Nivolumab
48 Study of Phenotypic and Functional Characteristics of Regulatory T Lymphocytes in Horton's Disease Unknown status NCT02857192 Not Applicable
49 Study of the T CD8 Immune Response in Horton's Disease Unknown status NCT02158208
50 Giant Cell Arteritis: Improving Use of Ultrasound Evaluation Unknown status NCT02523625

Search NIH Clinical Center for Central Nervous System Vasculitis

Genetic Tests for Central Nervous System Vasculitis

Anatomical Context for Central Nervous System Vasculitis

MalaCards organs/tissues related to Central Nervous System Vasculitis:

42
Brain, Lung, Bone, Heart, Spinal Cord, Endothelial, Neutrophil

Publications for Central Nervous System Vasculitis

Articles related to Central Nervous System Vasculitis:

(show top 50) (show all 184)
# Title Authors Year
1
MOG antibody disease manifesting as progressive cognitive deterioration and behavioral changes with primary central nervous system vasculitis. ( 30738279 )
2019
2
Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature. ( 30743080 )
2019
3
Primary central nervous system vasculitis in India - need for a multicenter prospective cohort study. ( 30860107 )
2019
4
Langerhans Cell Histiocytosis Causing Central Nervous System Vasculitis Leading to Stroke in a Two-year-old Boy: A Case Report. ( 30937249 )
2019
5
Central Nervous System Vasculitis Due to Substance Abuse. ( 30952417 )
2019
6
Central Nervous System Vasculitis due to Infection. ( 30952418 )
2019
7
Utility of diagnostic cerebral angiography in the management of suspected central nervous system vasculitis. ( 30952556 )
2019
8
A Long Interval from a Spinal Cord Lesion to a Subsequent Brain Lesion in Primary Central Nervous System Vasculitis. ( 30449796 )
2019
9
Recurrent strokes, central nervous system vasculitis, and acquired protein S deficiency secondary to varicella zoster in a child with AIDS. ( 30478796 )
2019
10
Primary central nervous system vasculitis mimicking brain tumor: Comprehensive analysis of 13 cases from a single institutional cohort of 191 cases. ( 30528173 )
2019
11
Anti-neutrophil cytoplasmic antibody associated central nervous system vasculitis with brain and spinal cord subarachnoid hemorrhage: A rare case report and review of the literature. ( 30594448 )
2019
12
A case of central nervous system vasculitis presenting as a mass-like lesion. ( 30610477 )
2019
13
Study on the Clinical, Imaging, and Pathological Characteristics of 18 Cases with Primary Central Nervous System Vasculitis. ( 30635219 )
2019
14
Hospital Onset Varicella Central Nervous System Vasculitis in a Patient with HIV Infection. ( 30715900 )
2019
15
Magnetic resonance imaging in central nervous system vasculitis in a patient affected by crioglobulin-negative hepatitis C virus infection: A likely correlation. ( 28735554 )
2018
16
Primary central nervous system vasculitis associated with lymphoma. ( 29429967 )
2018
17
Primary central nervous system vasculitis mimicking a brain tumor on conventional magnetic resonance imaging: the usefulness of perfusion-weighted imaging. A case report. ( 29516404 )
2018
18
The first case of bacillus Calmette-Guérin-induced small-vessel central nervous system vasculitis. ( 29740727 )
2018
19
Isolated Cervical Cord Involvement in Primary Central Nervous System Vasculitis. ( 29961677 )
2018
20
Treatment and Long-Term Outcomes of Primary Central Nervous System Vasculitis. ( 29986936 )
2018
21
FET PET in Primary Central Nervous System Vasculitis. ( 30080188 )
2018
22
Vessel wall enhancement on MRI in the diagnosis of primary central nervous system vasculitis. ( 30102571 )
2018
23
Central Nervous System Vasculitis for Cryptococcosis in an Immunocompetent Patient. ( 30200288 )
2018
24
Pyogenic Meningitis Complicated with Extensive Central Nervous System Vasculitis and Moyamoya Vasculopathy. ( 30271471 )
2018
25
High-Resolution Vessel Wall MRI : Appearance of Intravascular Lymphoma Mimics Central Nervous System Vasculitis. ( 27530660 )
2017
26
Usual and Unusual Manifestations of Systemic and Central Nervous System Vasculitis. ( 27894445 )
2017
27
Central nervous system vasculitis in adults: An update. ( 28087351 )
2017
28
Primary central nervous system vasculitis and its mimicking diseases - clinical features, outcome, comorbidities and diagnostic results - A case control study. ( 28324788 )
2017
29
Coccidioidal meningitis complicated by central nervous system vasculitis in a patient with leukemia. ( 28386527 )
2017
30
Central nervous system vasculitis in systemic lupus erythematosus: a case series report in a tertiary referral centre. ( 28420057 )
2017
31
Successful Treatment of Central Nervous System Vasculitis Associated with Relapsing Polychondritis With Cyclophosphamide. ( 28502337 )
2017
32
Primary Central Nervous System Vasculitis Mimicking a Cortical Brain Tumor: A Case Report. ( 28516076 )
2017
33
Focal Hemispheric Central Nervous System Vasculitis: An Unusual Form Of Primary Angiitis. ( 28718271 )
2017
34
Association of primary central nervous system vasculitis with the presence of specific human leucocyte antigen gene variant. ( 28734234 )
2017
35
Concordance of Time-of-Flight MRA and Digital Subtraction Angiography in Adult Primary Central Nervous System Vasculitis. ( 28751515 )
2017
36
Pitfalls of PACNS: A Rare Case of Central Nervous System Vasculitis Associated with Toxoplasmosis. ( 28765346 )
2017
37
Adult Primary Central Nervous System Vasculitis. ( 28786262 )
2017
38
Central nervous system vasculitis presenting as an ischaemic stroke in a young woman with systemic sclerosis. ( 28977489 )
2017
39
Central nervous system vasculitis imaging: Simplified. ( 29133684 )
2017
40
Central nervous system vasculitis in a patient with HIV infection: a diagnostic challenge. ( 29236897 )
2017
41
Unihemispheric central nervous system vasculitis. ( 29260024 )
2017
42
Case report of a 28-year-old male with the rapid progression of steroid-resistant central nervous system vasculitis diagnosed by a brain biopsy. ( 28804113 )
2017
43
Management of primary and secondary central nervous system vasculitis. ( 26599380 )
2016
44
Primary Central Nervous System Vasculitis With Optic Nerve Involvement. ( 26693942 )
2016
45
Isolated Central Nervous System Vasculitis as a Manifestation of Neurosarcoidosis. ( 27083067 )
2016
46
Central nervous system vasculitis in adults and children. ( 27112683 )
2016
47
Central nervous system vasculitis in pediatric microscopic polyangiitis. ( 27156236 )
2016
48
The Role of Catheter Angiography in the Diagnosis of Central Nervous System Vasculitis. ( 27781050 )
2016
49
Response to "High-Resolution Vessel Wall MRI: Appearance of Intravascular Lymphoma Mimics Central Nervous System Vasculitis". ( 27822627 )
2016
50
[A case of primary central nervous system vasculitis diagnosed by second brain biopsy and treated successfully]. ( 26960271 )
2016

Variations for Central Nervous System Vasculitis

Expression for Central Nervous System Vasculitis

Search GEO for disease gene expression data for Central Nervous System Vasculitis.

Pathways for Central Nervous System Vasculitis

Pathways related to Central Nervous System Vasculitis according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 CCR6 CRP HLA-DRB1 IFNG IL17A IL1B
2
Show member pathways
13.6 CCR6 IFNG IL17A IL1B IL6 TNF
3
Show member pathways
13.34 CCR6 IL17A IL1B IL6 TNF TNFRSF10A
4
Show member pathways
13.29 HLA-DRB1 IFNG IL17A IL1B IL6 TNF
5
Show member pathways
13.24 CCR6 IL17A IL1B IL6 TNF TNFRSF10A
6
Show member pathways
12.83 HLA-DRB1 IFNG IL17A IL1B IL6 TNF
7 12.54 IFNG IL17A IL1B MPO TNF
8
Show member pathways
12.52 IFNG IL17A IL1B IL6 TNF
9
Show member pathways
12.51 HLA-DRB1 IFNG IL17A IL1B IL6 TNF
10
Show member pathways
12.49 IFNG IL17A IL1B IL6 MPO TNF
11
Show member pathways
12.29 IFNG IL1B IL6 TNF
12
Show member pathways
12.29 IFNG IL17A IL1B IL6 TNF
13
Show member pathways
12.25 HLA-DRB1 IFNG IL1B TNF
14
Show member pathways
12.25 IFNG IL17A IL1B IL6 TNF
15
Show member pathways
12.2 IFNG IL1B TNF TNFRSF10A
16
Show member pathways
12.17 IFNG IL1B IL6 TNF
17 12.17 HLA-DRB1 IFNG IL1B IL6 TNF
18
Show member pathways
12.14 CRP IFNG IL1B IL6 MPO SERPINA3
19
Show member pathways
12.06 IFNG IL17A IL1B IL6 TNFRSF10A
20 12.04 IFNG IL1B TNF
21
Show member pathways
12.03 IFNG IL1B IL6 TNF
22 12 IFNG IL1B TNF
23 12 IFNG IL1B IL6 TNF
24 11.98 IFNG IL6 MPO TNF
25 11.96 IL17A IL1B IL6 TNF
26
Show member pathways
11.94 HLA-DRB1 IFNG IL1B
27
Show member pathways
11.94 IFNG IL17A IL1B IL6 TNF
28 11.93 IL1B IL6 TNF
29 11.91 IFNG IL1B IL6
30 11.89 HLA-DRB1 IL1B IL6 TNF
31 11.88 IL1B IL6 TNF
32 11.87 IFNG IL1B IL6 TNF
33 11.81 IFNG IL1B IL6
34 11.75 IL1B IL6 TNF
35 11.72 IFNG IL1B IL6 TNF
36 11.67 IL1B IL6 TNF
37 11.67 CCR6 IFNG IL17A IL1B TNF
38
Show member pathways
11.64 IFNG IL1B IL6 TNF
39 11.6 IL1B IL6 TNF
40 11.57 IFNG IL6 TNF
41 11.57 IFNG IL17A IL1B IL6 TNF
42 11.55 IL1B IL6 TNF
43 11.53 IL6 MPO TNF
44 11.53 IFNG IL1B TNF
45 11.52 IFNG IL1B TNF
46 11.5 IFNG IL1B IL6 TNF
47 11.41 IFNG IL1B IL6 TNF
48 11.39 HLA-DRB1 IFNG IL17A IL1B IL6 TNF
49 11.37 IL1B IL6 TNF
50 11.31 IL1B IL6 TNF

GO Terms for Central Nervous System Vasculitis

Cellular components related to Central Nervous System Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 CRP IFNG IL17A IL1B IL6 MPO
2 external side of plasma membrane GO:0009897 9.46 CCR6 HLA-DRB1 IL17A TNF
3 extracellular space GO:0005615 9.23 CRP IFNG IL17A IL1B IL6 MPO

Biological processes related to Central Nervous System Vasculitis according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.97 IFNG IL17A IL1B IL6 TNF
2 cytokine-mediated signaling pathway GO:0019221 9.93 IL17A IL1B IL6 TNF
3 positive regulation of gene expression GO:0010628 9.93 CRP IFNG IL1B IL6 TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.84 IL1B IL6 TNF
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.82 IL1B IL6 TNF
6 defense response to Gram-positive bacterium GO:0050830 9.81 CRP IL6 TNF
7 inflammatory response GO:0006954 9.8 CRP IL17A IL1B IL6 SERPINA3 TNF
8 regulation of insulin secretion GO:0050796 9.79 IFNG IL1B TNF
9 positive regulation of interleukin-6 production GO:0032755 9.77 IL1B IL6 TNF
10 extrinsic apoptotic signaling pathway GO:0097191 9.72 IFNG TNF TNFRSF10A
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.7 IFNG IL1B TNF
12 acute-phase response GO:0006953 9.69 CRP IL6 SERPINA3
13 humoral immune response GO:0006959 9.67 CCR6 IFNG IL6 TNF
14 positive regulation of chemokine production GO:0032722 9.66 IL6 TNF
15 negative regulation of lipid catabolic process GO:0050995 9.66 IL1B TNF
16 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.65 IL1B TNF
17 negative regulation of growth of symbiont in host GO:0044130 9.65 MPO TNF
18 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.65 IL1B TNF
19 negative regulation of neurogenesis GO:0050768 9.65 IL1B IL6 TNF
20 positive regulation of chemokine biosynthetic process GO:0045080 9.63 IL1B TNF
21 positive regulation of osteoclast differentiation GO:0045672 9.63 IFNG IL17A TNF
22 positive regulation of histone phosphorylation GO:0033129 9.62 CDK9 IL1B
23 regulation of establishment of endothelial barrier GO:1903140 9.62 IL1B TNF
24 response to glucocorticoid GO:0051384 9.61 IL6 TNF
25 positive regulation of glial cell proliferation GO:0060252 9.61 IL1B IL6 TNF
26 positive regulation of fever generation GO:0031622 9.59 IL1B TNF
27 positive regulation of interleukin-23 production GO:0032747 9.58 IFNG IL17A
28 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.58 IFNG IL1B TNF
29 sequestering of triglyceride GO:0030730 9.56 IL1B TNF
30 immune response GO:0006955 9.5 CCR6 HLA-DRB1 IFNG IL17A IL1B IL6
31 positive regulation of vitamin D biosynthetic process GO:0060557 9.49 IFNG TNF
32 negative regulation of lipid storage GO:0010888 9.43 CRP IL6 TNF
33 positive regulation of neuroinflammatory response GO:0150078 9.33 IL1B IL6 TNF
34 chronic inflammatory response to antigenic stimulus GO:0002439 9.27 TNF
35 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 8.8 IFNG IL1B TNF

Molecular functions related to Central Nervous System Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 IFNG IL17A IL1B IL6 TNF

Sources for Central Nervous System Vasculitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....